Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C

Abstract

Aim: To confirm the predictive factors for interferon (IFN)-alpha and ribavirin combination therapy for chronic hepatitis patients with hepatitis C virus (HCV) genotype 1b.

Methods: HCV RNA from 50 patients infected with HCV genotype 1b was studied by cloning and sequencing of interferon sensitivity determining region (ISDR), PKR-eIF2alpha phosphorylation homology domain (PePHD). Patients were treated with IFN-alpha and ribavirin for 6 mo and grouped by effectiveness of the therapy. A variety of factors were analyzed.

Results: Our data showed that age, HCV RNA titer, and ISDR type could be used as the predictive factors for combined IFN-alpha and ribavirin efficacy. Characteristically, mutations in PePHD appeared only when the combination therapy was effective. Other factors, such as sex and alanine aminotransferase (ALT) level, were not related to its efficacy. Adjusting for age and HCV RNA titer indicated that the ISDR type was the most potent predictive factor.

Conclusion: HCV RNA ISDR type is an important factor for predicting efficacy of IFN-alpha and ribavirin combination therapy in Korean patients.

Figure 1

ISDR sequences (2209-2248) of HCV in complete response group (A) and in no-response group (B). Dashes indicate the amino acid residues identical to the sequences on the top in each panel.

Figure 2

PePHD sequences (659-670) of HCV in complete response group (n = 21) and no-response group (n = 29). Dashes indicate the amino acid residues identical to the sequences on the top in each panel.